Who Should Not Microdose: A Complete Contraindications Guide

Why a Contraindications Guide Matters

Most microdosing content centres on what people might gain from the practice. Far less attention goes to who might be harmed by it. That imbalance matters. A 2023 survey published in Scientific Reports (Rootman et al.) found that roughly 18% of microdosers reported at least one unwanted effect, ranging from increased anxiety to mood destabilisation. For certain populations, those risks are substantially higher.

Responsible practice means knowing when not to practise. Without large-scale, placebo-controlled clinical trials dedicated to microdosing safety, our understanding of contraindications draws on adjacent evidence: full-dose psychedelic research, pharmacological knowledge of serotonin receptor activity, clinical observation, and self-report data. That evidence, while imperfect, is enough to identify clear situations where microdosing carries meaningful risk.

This guide is designed to help you make an informed, honest assessment of whether microdosing is appropriate for you right now. It is not a replacement for professional medical advice.

A Note on Evidence and Limitations

Most of what we know about psychedelic contraindications comes from full-dose research, where exclusion criteria in clinical trials (such as those run by Johns Hopkins, Imperial College London, and MAPS) serve as a proxy for established risk factors. Whether these risks translate proportionally to sub-perceptual doses is unknown. The precautionary principle applies: where the potential for serious harm exists, caution is the appropriate default.

Personal or Family History of Psychotic Disorders

This is the most widely agreed-upon contraindication in the psychedelic research community, and it extends to microdosing. Conditions including schizophrenia, schizoaffective disorder, and bipolar I with psychotic features all involve disruptions in dopaminergic and serotonergic signalling. Psilocybin and other classical psychedelics act primarily on 5-HT2A receptors, the same receptors implicated in psychotic symptom generation.

Every major clinical trial of psilocybin to date, from the Johns Hopkins depression studies (Davis et al., 2021, JAMA Psychiatry) to Imperial College's treatment-resistant depression trials (Carhart-Harris et al., 2021, New England Journal of Medicine), excludes participants with a personal or first-degree family history of psychotic disorders. The concern is not theoretical. Full-dose psychedelics have been documented to precipitate psychotic episodes in vulnerable individuals, and while sub-perceptual doses involve far less receptor activation, the threshold at which risk begins is simply not known.

First-degree family history (a parent, sibling, or child with a psychotic disorder) is considered a risk factor even if you have never experienced symptoms yourself. The genetic vulnerability for psychosis can remain latent, and serotonergic compounds may act as a trigger. For a deeper look at the receptor mechanisms involved, see our article on the neuroscience of microdosing.

Bipolar Disorder

Bipolar disorder, both type I and type II, presents a distinct set of risks. The primary concern is that serotonergic stimulation can trigger manic or hypomanic episodes. This is well-documented with SSRIs (which is why mood stabilisers are typically co-prescribed in bipolar depression), and the mechanism is relevant to psilocybin as well.

A 2022 case series published in Journal of Psychopharmacology (Ling et al.) described manic episodes following psilocybin use in individuals with bipolar disorder, including cases where the individual was previously stable. While these cases involved higher doses, the serotonergic mechanism does not have a clearly defined safe threshold for people with bipolar vulnerability.

Bipolar II is sometimes perceived as "milder," but hypomania carries its own serious risks, including impulsive decision-making, sleep disruption, and subsequent depressive crashes. If you are taking mood stabilisers such as lithium or valproate, there are additional pharmacological concerns. Our medication interactions guide covers these in detail, particularly the significant risks associated with lithium and psilocybin.

Severe Anxiety or Panic Disorders

This one catches many people off guard. Anxiety reduction is one of the most commonly cited motivations for microdosing, with a 2021 survey by Hutten et al. (Psychopharmacology) finding that 21% of microdosers reported anxiety management as a primary goal. Yet for people with severe or clinical anxiety, particularly panic disorder, generalised anxiety disorder at the clinical end of the spectrum, or PTSD, microdosing can make things worse.

Even sub-perceptual doses of psilocybin increase serotonergic activity and can subtly shift arousal states. For someone whose nervous system is already in a state of heightened threat detection, even a small increase in physiological arousal, a slightly elevated heart rate, a mild shift in perception, can be interpreted by the brain as danger. This can feed back into the anxiety loop rather than interrupting it.

A 2022 naturalistic study by Kuypers et al. (Frontiers in Psychiatry) noted that participants with higher baseline anxiety were more likely to report increased anxiety as a microdosing side effect. The relationship appears dose-responsive but also highly individual.

When Anxiety Gets Worse, Not Better

If you are already microdosing and noticing that anxiety is increasing rather than decreasing, pay attention. Signs to watch for include heightened restlessness on dosing days, increased rumination or looping thoughts, difficulty sleeping after a microdose, a sense of being "on edge" that was not present before, and panic symptoms (chest tightness, shortness of breath, derealization) appearing or worsening.

Honest self-tracking is essential here. The mind is remarkably good at explaining away patterns, especially when you are hopeful that something will help. Journaling consistently, noting both good days and difficult ones, is how you catch a worsening trend before it becomes entrenched. Afterglow's journaling tool is designed for exactly this kind of pattern recognition, helping you see what is actually changing over time rather than relying on memory alone.

Medication Conflicts

Medication interactions represent one of the most concrete and pharmacologically grounded contraindication categories. We cover this topic in depth in our dedicated medication interactions article and our specific piece on microdosing and SSRIs, but the key categories deserve a summary here.

SSRIs and SNRIs: These medications and psilocybin both act on the serotonin system. The combination raises the theoretical risk of serotonin syndrome, a potentially life-threatening condition involving agitation, hyperthermia, rapid heart rate, and in severe cases, seizures. While the risk at sub-perceptual doses is likely lower than with full doses, it is not zero. Many people also report that SSRIs blunt or eliminate the effects of microdosing, leading some to reduce their medication without medical guidance, a dangerous practice in itself.

Lithium: The combination of lithium and psychedelics has been flagged repeatedly in clinical literature and harm reduction communities. Seizures and psychotic episodes have been reported. This is widely regarded as one of the highest-risk combinations.

MAOIs: Monoamine oxidase inhibitors prevent the breakdown of serotonin, dramatically increasing the risk of serotonin syndrome when combined with any serotonergic compound. This includes certain antidepressants (phenelzine, tranylcypromine) and the ayahuasca component harmine/harmaline.

If you are on any prescription medication, speak with your healthcare provider before beginning a microdosing practice. Do not adjust your medication without professional guidance.

Pregnancy and Breastfeeding

There is no safety data on microdosing during pregnancy or breastfeeding. None. No clinical trials, no observational studies of sufficient size, no established safety profile. In the absence of evidence, the precautionary principle is clear: do not microdose while pregnant or breastfeeding.

Serotonin plays a critical role in foetal development, influencing neural tube formation, cardiac development, and brain organisation. Psilocybin's activity at 5-HT2A receptors means it has the potential to interfere with these processes, though the specific risk at sub-perceptual doses is unstudied. Animal studies on higher-dose psilocybin have shown mixed but concerning effects on embryonic development (Thompson & Rickli, 2019). Psilocybin and its active metabolite psilocin are also likely to cross the placental barrier and pass into breast milk.

This is one area where the answer is straightforward, not because we know microdosing causes harm during pregnancy, but because we have no evidence that it does not.

Cardiovascular Conditions

This is a concern that gets less attention than it deserves. Psilocybin activates 5-HT2B receptors, and chronic stimulation of these receptors has been linked to cardiac valvulopathy, the thickening and dysfunction of heart valves. This was the mechanism behind the withdrawal of the appetite suppressant fenfluramine (the "fen" in fen-phen) in the late 1990s.

A 2023 analysis by Flanagan et al. (Journal of Psychopharmacology) flagged this as a theoretical concern specifically for repeated, long-term microdosing, where the frequency of 5-HT2B activation could accumulate over months or years. The risk from occasional or short-term use appears low, but for people with pre-existing heart valve conditions, structural heart disease, or other cardiovascular concerns, even a theoretical risk warrants caution.

Our heart health and microdosing article explores this topic in much greater depth, including what current research does and does not tell us about long-term cardiac safety.

Young People and Adolescents

There is no research on microdosing in people under 18, and very little on young adults under 25. The serotonin system plays a central role in brain development, and the prefrontal cortex, the region responsible for executive function, impulse control, and emotional regulation, continues maturing into the mid-twenties.

Introducing exogenous serotonergic compounds during this developmental window carries unknown risks. Animal studies on adolescent rodents exposed to psychedelics have shown altered serotonin receptor density and behavioural changes into adulthood (Catlow et al., 2013, Experimental Brain Research), though translating rodent findings to humans is always imprecise.

Every major psychedelic clinical trial restricts participation to adults, typically aged 21 or older, and often 25 or older. Until dedicated research exists, strong caution is warranted for young people, regardless of how mature or well-informed they may feel.

Active Substance Use Disorders

This requires nuance. There is promising research on full-dose psilocybin-assisted therapy for alcohol use disorder (Bogenschutz et al., 2022, JAMA Psychiatry) and tobacco dependence (Johnson et al., 2014, Journal of Psychopharmacology). But these studies involve supervised, therapeutic contexts with professional support, and they use full doses, not microdoses.

Microdosing is a different practice. For someone with an active substance use disorder, there are specific concerns. Replacing one substance-dependent pattern with another is a real risk, even when the new substance is perceived as "natural" or "healing." The self-directed nature of microdosing, without the therapeutic container that makes full-dose research effective, may not provide the accountability and support that recovery demands.

If you are navigating substance use challenges, professional support should come first. A therapist or addiction specialist can help you evaluate whether microdosing might have a role in your recovery, or whether it could complicate it.

Honest tracking matters most when the stakes are high. Afterglow's journaling tool helps you notice patterns in mood, energy, and wellbeing, so you are working with data rather than guesswork.

Situational Contraindications

Not all contraindications are clinical. Sometimes the issue is not who you are but where you are in life. Periods of acute grief, recent trauma, major life upheaval (divorce, job loss, bereavement), or sustained high stress can make even subtle mood shifts destabilising.

Microdosing does not occur in a vacuum. Even at sub-perceptual levels, the practice can subtly influence emotional processing. When your baseline is already fragile, amplifying that processing, even slightly, may not be helpful. Similarly, environments where even minor cognitive shifts could be unsafe (operating heavy machinery, safety-critical work, driving) should be considered. If your professional life involves these kinds of demands, timing and protocol choice become especially important.

Personality Disorders and Complex Trauma

People living with certain personality disorders, particularly borderline personality disorder, or unprocessed complex trauma may find that microdosing's subtle emotional amplification effects are destabilising rather than clarifying. Emotional regulation is already a central challenge in these conditions, and introducing a serotonergic variable without professional guidance can complicate things.

This is not a blanket prohibition. It is a strong recommendation that anyone in this situation work with a trauma-informed therapist who can help evaluate whether microdosing is appropriate and provide support if difficult material surfaces.

How to Make an Honest Assessment

The hardest part of any contraindications guide is the self-honesty it requires. It is tempting to read through a list like this and find reasons why each category does not quite apply to you. That is a very human response, especially when you are hoping microdosing might help.

Consider these questions honestly:

• Do I have a personal or family history of psychosis, bipolar disorder, or schizophrenia?
• Am I currently taking any medication that affects serotonin?
• Is my anxiety or mental health at a level of severity that really warrants professional treatment rather than self-directed experimentation?
• Am I in a stable enough emotional place to handle the possibility that microdosing might bring up difficult feelings?
• Do I have someone I trust, a friend, partner, or therapist, I can talk to if things feel off?
• Am I considering microdosing as a substitute for professional help I know I need?

If you answered yes to any of the first three, consulting a healthcare provider is not optional, it is necessary. Afterglow's reflective journaling can support self-awareness, but it is not a replacement for clinical assessment when clinical questions are on the table.

When to Stop if You Have Already Started

Perhaps you have already begun a protocol and something does not feel right. Knowing when to stop is just as important as knowing whether to start. Stopping is not failure. It is one of the most responsible decisions you can make.

Red flags that suggest you should pause or stop your protocol:

• Increased anxiety or panic symptoms that were not present or were less severe before you started
• Mood instability, particularly rapid cycling between emotional states
• Sleep disruption that persists across multiple dosing cycles (see our article on sleep and rest for more context)
• Dissociation or derealization, feeling detached from yourself or your surroundings
• Obsessive or looping thoughts that increase on dosing days
• Heart palpitations or cardiovascular symptoms
• A general sense that something is off, even if you cannot articulate exactly what

If you experience any of these, stop your protocol and consult a healthcare provider. Our guide on what to do if effects feel too strong provides immediate practical steps. Trust your own signal. No protocol is worth pushing through when your body or mind is telling you to stop.

Track what matters. Afterglow's pattern recognition tools help you spot shifts in mood, sleep, and anxiety early, so you can make informed decisions about whether to continue, adjust, or pause.

The Bottom Line

Microdosing is not for everyone, and recognising that is not a limitation of the practice. It is a feature of engaging with it responsibly. The categories outlined here, psychotic disorders, bipolar disorder, severe anxiety, medication conflicts, pregnancy, cardiovascular conditions, young age, active substance use disorders, and certain situational factors, represent our current best understanding of where the risk-benefit equation does not favour microdosing.

That understanding will evolve. As dedicated microdosing safety research emerges, some of these contraindications may become more nuanced or more definitive. For now, the responsible path is to take them seriously, to consult a qualified healthcare provider when any of these factors are relevant to your life, and to remember that the decision not to microdose can be just as intentional as the decision to begin.

Legal status of psilocybin and other microdosing substances varies significantly by jurisdiction. Always familiarise yourself with the laws in your region.